杨智冉, 苏延冬, 杨锐, 吴合亮, 李雁. 肿瘤细胞减灭术联合腹腔热灌注治疗恶性腹膜间皮瘤的并发症及危险因素分析[J]. 中国肿瘤临床, 2023, 50(13): 661-666. DOI: 10.12354/j.issn.1000-8179.2023.20230371
引用本文: 杨智冉, 苏延冬, 杨锐, 吴合亮, 李雁. 肿瘤细胞减灭术联合腹腔热灌注治疗恶性腹膜间皮瘤的并发症及危险因素分析[J]. 中国肿瘤临床, 2023, 50(13): 661-666. DOI: 10.12354/j.issn.1000-8179.2023.20230371
shu
Zhiran Yang, Yandong Su, Rui Yang, Heliang Wu, Yan Li. Analysis of risk factors and complications of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(13): 661-666. DOI: 10.12354/j.issn.1000-8179.2023.20230371
Citation: Zhiran Yang, Yandong Su, Rui Yang, Heliang Wu, Yan Li. Analysis of risk factors and complications of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(13): 661-666. DOI: 10.12354/j.issn.1000-8179.2023.20230371
shu

肿瘤细胞减灭术联合腹腔热灌注治疗恶性腹膜间皮瘤的并发症及危险因素分析

Analysis of risk factors and complications of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma

    摘要
  • 摘要:
      目的  分析肿瘤细胞减灭术（cytoreductive surgery，CRS）联合腹腔热灌注化疗（hyperthermic intraperitoneal chemotherapy，HIPEC）治疗恶性腹膜间皮瘤（malignant peritoneal mesothelioma，MPM）的并发症及其影响因素，预防严重不良事件（serious adverse events，SAEs）发生。
      方法  收集2015年4月至2022年11月在首都医科大学附属北京世纪坛医院行CRS+HIPEC治疗的154例MPM患者临床病理资料，统计术后并发症发生情况，分析影响SAEs的危险因素。
      结果  共计154例MPM患者接受CRS+HIPEC治疗，1级不良事件10例（8.8%），2级41例（36.3%），3级53例（46.9%），4级7例（6.2%），5级2例（1.8%）。需要进行抢救的SAEs发生率为5.8%（9/154），围手术期死亡率1.3%（2/154）。单因素分析表明，腹膜癌指数（peritoneal cancer index，PCI）（P=0.036）、肿瘤细胞减灭程度（completeness of cytoreduction，CC）（P=0.004）、腹膜剥除区域数量（P=0.035）及术前CA125水平（P=0.025）为影响SAEs发生的预后因素。多因素分析显示，腹膜剥除区域数量（OR=0.360，P=0.024）、CC评分（OR=0.325，P=0.003）是影响SAEs发生的独立危险因素。
      结论   在提高疗效实现完全CRS同时，合理把握肿瘤细胞减灭程度，可能是目前减少并发症，尤其是降低SAEs发生率、提高手术安全性的关键。

     

    Abstract:
      Objective  To analyze complications of malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and identify the associated risk factors to prevent serious adverse events (SAEs).
      Method  Clinicopathological information from 154 patients with MPM, who underwent treatment with CRS+HIPEC, enrolled in Beijing Shijitan Hospital, Capital Medical University from April 2015 to November 2022 was retrospectively analyzed. The incidence of postoperative complications was statistically analyzed, and risk factors affecting SAEs were evaluated.
      Results  Among 154 MPM patients, adverse events occurred as follows: grade 1, n=10 (8.8%); grade 2, n=41 (36.3%); grade 3, n=53 (46.9%); grade 4, n=7 (6.2%); and grade 5, n=2 (1.8%). No adverse events were reported in 41 patients. The rate of SAEs requiring rescue was 5.8% (9/154), and the perioperative mortality rate was 1.3% (2/154). Univariate analysis revealed that peritoneal cancer index (PCI) (P=0.036), completeness of cytoreduction (CC) (P=0.004), number of peritoneal exfoliated areas (P=0.035), and preoperative CA125 level (P=0.025) were prognostic factors. Multivariate analysis revealed that the number of peritoneal exuded areas (odds ratio OR=0.360, P=0.024) and CC score (OR=0.325, P=0.003) were independent risk factors.
      Conclusions  To improve the therapeutic effect of achieving complete CRS, a reasonable grasp of the extent of CRS may be an important factor in reducing complications, especially the incidence of SAEs, and improving surgical safety.

     

    • HTML全文
    • 参考文献(16)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回